Global Infectious Diseases Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Infectious Diseases Market Segmentation, By Product and Services (Assays, Kits and Reagents, Instruments, Services, and Software), Technology (Immunodiagnostics, Clinical Microbiology, Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and Next-Generation Sequencing (NGS), DNA Microarray, and Other Technologies), Disease Type (Hepatitis, Human Immunodeficiency Virus (HIV), Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG), Hospital-Acquired Infections (HAIS), Human Papillomavirus (HPV), Tuberculosis (TB), Influenza, and Other Infectious Diseases), End User (Hospital/Clinical Laboratories, Reference Laboratories, Physician Offices, Academic/Research Institutes, and Other End Users) - Industry Trends and Forecast to 2032

Infectious Diseases Market Size

• The global infectious diseases market size was valued at USD 21.70 billion in 2024 and is expected to reach USD 33.99 billion by 2032, at a CAGR of 5.77% during the forecast period
• The market expansion is primarily driven by the rising prevalence of infectious diseases worldwide, such as HIV, tuberculosis, hepatitis, and emerging viral infections, necessitating enhanced diagnostics, treatments, and vaccines
• In addition, increased public health initiatives, growing investments in R&D, and global awareness about rapid response to outbreaks are reinforcing the market demand. These combined dynamics are driving innovation and adoption of advanced infectious disease management solutions, thereby substantially fueling market growth

Infectious Diseases Market Analysis

• Infectious diseases, caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, continue to pose significant global health challenges, driving demand for advanced diagnostics, therapeutics, and preventive solutions across both developed and developing regions
• The accelerating demand for infectious disease solutions is fueled by the increasing incidence of emerging and re-emerging infections, antimicrobial resistance, global travel, and aging populations with weakened immune responses
• North America dominated the infectious diseases market with the largest revenue share of 38.5% in 2024, characterized by robust healthcare infrastructure, high healthcare spending, and the presence of leading pharmaceutical and biotechnology companies actively engaged in vaccine and drug development
• Asia-Pacific is expected to be the fastest growing region in the infectious diseases market during the forecast period due to rising investments in healthcare infrastructure, government-led immunization initiatives, and a growing patient population susceptible to infectious outbreaks
• Polymerase Chain Reaction (PCR), segment dominated the infectious diseases market with a market share of 35.4% in 2024, driven by its high sensitivity, rapid turnaround time, and broad applicability in detecting a wide range of pathogens accurately

Report Scope and Infectious Diseases Market Segmentation

Infectious Diseases Market Trends

“Shift Toward Rapid, AI-Driven Diagnostics and Decentralized Testing”

• A significant and accelerating trend in the global infectious diseases market is the growing integration of artificial intelligence (AI) with rapid diagnostic technologies and point-of-care testing platforms. This convergence is significantly enhancing the speed, accuracy, and accessibility of infectious disease detection across various healthcare environments

  • For instance, BioFire’s FilmArray system and Abbott’s ID NOW offer rapid molecular testing with AI-supported result interpretation, enabling clinicians to detect multiple pathogens in a single test with minimal hands-on time. Similarly, companies such as PathAI and Aidoc are leveraging AI to improve diagnostic imaging and pattern recognition for infectious conditions

• AI integration in diagnostics enables features such as automated analysis, outbreak prediction, and intelligent triaging of results, while portable and user-friendly devices support decentralized testing in remote or resource-limited settings. For instance, mobile-based diagnostic tools and handheld PCR systems are helping expand early detection capabilities outside traditional laboratory infrastructures
• The seamless fusion of AI and rapid diagnostics with digital healthcare platforms facilitates centralized disease monitoring, faster clinical decisions, and more efficient public health responses. Through connected systems, healthcare providers can track, analyze, and respond to infection trends in real time
• This trend toward intelligent, fast, and widely accessible diagnostic solutions is fundamentally reshaping global infectious disease management. Consequently, companies such as Cepheid and QuidelOrtho are developing AI-enabled, compact diagnostic devices designed for both clinical and non-clinical environments
• The demand for diagnostic tools that offer real-time insights, AI-driven accuracy, and decentralized usability is growing rapidly across global markets, as healthcare systems increasingly prioritize preparedness, early intervention, and efficient outbreak containment.

Infectious Diseases Market Dynamics

Driver

“Rising Disease Burden and Demand for Rapid Diagnostics & Treatment”

• The increasing global burden of infectious diseases, including both emerging and re-emerging pathogens, is a significant driver fueling the demand for advanced diagnostic tools, effective treatments, and preventive healthcare measures across all healthcare settings

  • For instance, in March 2024, Cepheid announced the expansion of its Xpert Xpress menu with rapid, multiplex molecular tests for respiratory and bloodstream infections, supporting real-time clinical decision-making and reinforcing the importance of fast diagnostics in infection control

• As the incidence of infectious diseases such as influenza, HIV, tuberculosis, and hospital-acquired infections continues to rise, healthcare providers and public health authorities are increasingly prioritizing early detection and timely intervention to reduce morbidity and prevent outbreaks
• Furthermore, heightened global awareness of pandemic preparedness and investment in healthcare infrastructure are encouraging the adoption of innovative diagnostic and therapeutic solutions for infectious diseases, particularly in low- and middle-income regions
• The demand for rapid, accurate, and accessible testing technologies—especially point-of-care diagnostics—and the development of targeted antimicrobial therapies are key factors driving market growth. The rise in funding from governments and private sectors for infectious disease research and the proliferation of mobile and AI-powered diagnostic platforms are further accelerating the industry’s expansion

Restraint/Challenge

“Data Privacy Concerns and High Cost of Advanced Diagnostic Technologies”

• Concerns surrounding data privacy, especially in the context of digital and AI-driven infectious disease diagnostics, pose a significant challenge to wider market acceptance. As these technologies rely heavily on electronic health records and cloud-based platforms, they are susceptible to data breaches and unauthorized access, raising concerns among healthcare providers and patients asuch as

  • For instance, multiple reports in recent years of breaches in healthcare IT systems have highlighted vulnerabilities in handling sensitive patient data, prompting regulatory scrutiny and hesitancy in fully adopting digital diagnostic tools

• Addressing these data security concerns through strict compliance with global privacy regulations (such as GDPR and HIPAA), end-to-end encryption, and secure data storage protocols is essential to foster trust and ensure responsible data handling in infectious disease management
• In addition, the relatively high cost of advanced diagnostic solutions such as next-generation sequencing (NGS), multiplex PCR systems, and AI-integrated platforms can limit access in price-sensitive regions. Despite their clinical benefits, such tools may remain financially inaccessible to small clinics or underfunded health systems, particularly in developing economies
• While ongoing innovations and scaling are gradually improving affordability, the upfront investment and required technical expertise for deploying high-end infectious disease diagnostics continue to be major barriers
• Overcoming these challenges through transparent data policies, strengthened cybersecurity infrastructure, and broader availability of cost-effective diagnostic solutions will be essential to achieving equitable and scalable growth in the global infectious diseases market

Infectious Diseases Market Scope

The market is segmented on the basis of product and services, technology, disease type, and end user.

• By Product And Services

On the basis of product and services, the infectious diseases market is segmented into assays, kits and reagents; instruments; services; and software. The assays, kits, and reagents segment dominated the market with the largest revenue share in 2024, owing to their indispensable role in diagnostic testing, rapid detection, and monitoring of a wide range of infectious diseases. These products are widely used across point-of-care and laboratory-based settings due to their speed, ease of use, and growing availability in multiplex formats that allow for simultaneous detection of multiple pathogens.

The software segment is projected to witness the fastest growth rate from 2025 to 2032, driven by the increasing incorporation of AI and data analytics in diagnostic platforms. Software plays a critical role in integrating, analyzing, and interpreting diagnostic results in real-time, enhancing the precision and efficiency of disease detection and outbreak tracking.

• By Technology

On the basis of technology, the market is segmented into immunodiagnostics, clinical microbiology, polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), DNA sequencing and next-generation sequencing (NGS), DNA microarray, and other technologies. The PCR segment held the largest market share of 35.4% in 2024, attributed to its unparalleled sensitivity and specificity in detecting low concentrations of pathogens. PCR is widely adopted for diagnosing diseases such as COVID-19, HIV, TB, and influenza due to its speed, accuracy, and ability to amplify target DNA or RNA sequences.

The next-generation sequencing (NGS) segment is expected to register the fastest CAGR during the forecast period, fueled by its application in pathogen genome sequencing, antimicrobial resistance profiling, and real-time outbreak surveillance. Its ability to provide comprehensive molecular insights and support epidemiological studies is transforming infectious disease diagnostics.

• By Disease Type

On the basis of disease type, the infectious diseases market is segmented into hepatitis, human immunodeficiency virus (HIV), chlamydia trachomatis genital infection and gonorrhea (CT/NG), hospital-acquired infections (HAIs), human papillomavirus (HPV), tuberculosis (TB), influenza, and other infectious diseases. The HIV segment accounted for the largest market share in 2024, driven by extensive global screening programs, routine monitoring, and increasing awareness and availability of HIV diagnostics in both developed and developing countries.

The hospital-acquired infections (HAIs) segment is projected to grow at the highest CAGR from 2025 to 2032, due to the rising burden of multi-drug-resistant pathogens, growing hospitalization rates, and stringent infection control protocols implemented across healthcare facilities.

• By End User

On the basis of end user, the market is segmented into hospital/clinical laboratories, reference laboratories, physician offices, academic/research institutes, and other end users. The hospital/clinical laboratories segment dominated the market in 2024, supported by the high volume of diagnostic testing, advanced laboratory infrastructure, and the central role of hospitals in the diagnosis and treatment of infectious diseases.

The reference laboratories segment is expected to witness the fastest growth over the forecast period, driven by the increasing outsourcing of complex molecular and sequencing-based diagnostics, as well as the demand for high-throughput, accurate, and cost-effective services.

Infectious Diseases Market Regional Analysis

• North America dominated the infectious diseases market with the largest revenue share of 38.5% in 2024, driven by robust healthcare infrastructure, high healthcare spending, and the presence of leading pharmaceutical and biotechnology companies actively engaged in vaccine and drug development
• The strong demand for early detection and routine screening especially for diseases such as HIV, influenza, and hepatitis is fueling market growth. Government-led public health initiatives and robust insurance coverage further enhance access to diagnostic services
• In addition, continuous investments in advanced diagnostic technologies such as PCR and NGS, as well as rising outbreaks of hospital-acquired infections and antimicrobial resistance, are reinforcing the region’s leadership in the global infectious diseases diagnostics landscape

U.S. Infectious Diseases Market Insight

The U.S. infectious diseases market captured the largest revenue share of 42% in North America in 2024, driven by advanced healthcare infrastructure and widespread adoption of cutting-edge diagnostic technologies such as PCR and NGS. The increasing prevalence of infectious diseases such as HIV, hepatitis, and hospital-acquired infections, combined with government initiatives supporting disease surveillance and early diagnosis, is fueling market growth. In addition, the expanding network of clinical laboratories and reference labs enhances accessibility to rapid and accurate diagnostic services.

Europe Infectious Diseases Market Insight

The Europe infectious diseases market is projected to grow at a steady CAGR throughout the forecast period, supported by stringent healthcare regulations and rising awareness of infectious disease prevention and control. Growing public health expenditures and the adoption of advanced diagnostic platforms in countries such as Germany, France, and the U.K. are key growth drivers. The focus on early diagnosis and management of diseases such as tuberculosis, HPV, and influenza is promoting the demand for innovative testing solutions across hospitals and research institutions.

U.K. Infectious Diseases Market Insight

The U.K. infectious diseases market is expected to witness substantial growth during the forecast period due to increased investments in healthcare infrastructure and a growing focus on preventive diagnostics. Rising incidence rates of infectious diseases and the government’s active role in promoting vaccination and screening programs are encouraging adoption of advanced diagnostic assays and services. The country’s strong clinical research environment further propels demand for next-generation technologies.

Germany Infectious Diseases Market Insight

The Germany infectious diseases market is anticipated to grow at a considerable CAGR, driven by the country’s robust healthcare system and emphasis on technological innovation. Rising cases of hospital-acquired infections and antimicrobial resistance are stimulating demand for rapid and accurate diagnostic tools. Germany’s focus on sustainability and data privacy also influences the adoption of secure and efficient infectious disease diagnostics, especially in hospital and reference laboratory settings.  

Asia-Pacific Infectious Diseases Market Insight

The Asia-Pacific infectious diseases market is poised to expand at the fastest CAGR from 2025 to 2032, fueled by increasing healthcare awareness, government initiatives to control infectious diseases, and rising investments in healthcare infrastructure across countries such as China, India, and Japan. Rapid urbanization, expanding clinical laboratory networks, and the adoption of cost-effective diagnostic technologies are accelerating market growth. In addition, the high burden of infectious diseases in the region drives demand for widespread screening and monitoring.

Japan Infectious Diseases Market Insight

The Japan infectious diseases market is growing steadily due to the country’s advanced healthcare infrastructure and focus on precision diagnostics. Increasing prevalence of diseases such as influenza and tuberculosis, alongside rising demand for integration of infectious disease testing with broader healthcare IT systems, propels market expansion. Japan’s aging population also elevates the need for reliable and user-friendly diagnostic solutions in clinical and research settings.

India Infectious Diseases Market Insight

The India infectious diseases market accounted for the largest revenue share in Asia-Pacific in 2024, supported by high disease burden and government programs promoting early diagnosis and disease control. Rapid urbanization, expanding healthcare access, and increased availability of affordable assays and diagnostic kits drive the market. The growing network of hospital laboratories and academic research centers further supports adoption of advanced molecular diagnostic technologies in infectious disease detection and management.

Infectious Diseases Market Share

The infectious diseases industry is primarily led by well-established companies, including:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbott (U.S.)
• BIOMÉRIEUX (France)
• BD (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Hologic, Inc. (U.S.)
• QIAGEN (Netherlands)
• Danaher Corporation (U.S.)
• Siemens Healthineers AG (Germany)
• Cepheid (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Merck KGaA (Germany)
• GenMark Diagnostics, Inc. (U.S.)
• OraSure Technologies, Inc. (U.S.)
• Luminex Corporation (U.S.)
• Theradiag SA (France)
• Chembio Diagnostic Systems, Inc. (U.S.)
• QuidelOrtho Corporation (U.S.)
• Seegene Inc. (South Korea)
• Diasorin S.p.A. (Italy)

SKU-53759